University of Michigan Rogel Cancer Center
This clinical trial tests how well a type of non-invasive brain stimulation called transcranial direct current stimulation (tDCS) works to treat chemotherapy induced peripheral neuropathy (CIPN) in cancer survivors. CIPN is numbness, tingling, pain, and movement problems that can develop after chemotherapy as a result of changes to the nerves. A non-invasive form of brain stimulation called tDCS, applied to the area of the brain involved in sensation and movement, can temporarily improve the ability to detect vibration and temperature, as well as balance and walking, which may improve sensation and reduce pain in cancer survivors with CIPN.
Inclusion Criteria: * 18 to 85 years of age * Diagnosis of cancer, stages I-IV * Cancer survivor (not currently receiving chemotherapy, radiation, or immunotherapy) * Presence of CIPN defined as new, length-dependent numbness, tingling, and/or pain that developed with neurotoxic chemotherapy * CIPN20 score ≥ 20 * Able to walk unassisted * Proficient in English Exclusion Criteria: * Known brain metastases * Known neurological conditions aside from chemotherapy-induced peripheral neuropathy (CIPN) * History of brain or spinal surgery * Neuropathy other than CIPN * Significant hearing or visio…
Undergo sham tDCS
Ancillary studies
Undergo tDCS
Arctuva estimate
Verify or correct the compensation shown for this listing.